Welcome to our dedicated page for ACHIKO NAMEN AKT news (Ticker: ACHKF), a resource for investors and traders seeking the latest updates and insights on ACHIKO NAMEN AKT stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ACHIKO NAMEN AKT's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ACHIKO NAMEN AKT's position in the market.
Achiko AG has signed a major deal with Pengurus Wilayah Nahdlatul Ulama DKI Jakarta to provide Covid-19 test AptameX to its members, starting with four million in Jakarta. This collaboration aims to support frequent testing as part of Indonesia's 3T Covid-19 management program. The company has also reorganized contracts with PT Indofarma to produce one million test kits initially, scaling up to over ten million monthly within a year. Furthermore, Achiko plans to expand its diagnostics to other diseases, including Dengue, leveraging its telehealth platform, Teman Sehat.
Achiko AG (OTCQB: ACHKF) has finalized an Equity Subscription Agreement with RiverFort Global Opportunities PCC Limited to raise up to USD $10.5 million over 36 months for AptameX production in Indonesia and business expansion related to Covid-19 diagnostics. Additionally, a USD $2.1 million unsecured loan facility has been secured. The funding will facilitate the production of approximately 1,000,000 Covid-19 test kits. Achiko aims to advance its capabilities in global diagnostics, with plans for wider marketing following successful testing against variants.
Achiko AG has announced progress on its Covid-19 testing platform, AptameX™, reporting the completion of pre-sales validation testing in Indonesia. The company is establishing a supply chain from Taiwan and aims to meet global demand through resources in Taiwan, Spain, and Australia. As part of its international expansion, it is initiating a clinical investigation report in Australia. Achiko's unique DNA aptamer chemistry enhances performance compared to existing rapid tests. The company anticipates acceleration as travel restrictions ease.
Achiko AG has released a draft paper detailing the results of a calibration study for its DNA Aptamer Gold Nanoparticle Colorimetric Diagnostic Test Kit for SARS-CoV-2. This test, part of AptameX™, achieved over 97% sensitivity and specificity in controlled trials with 58 human samples. The company is now sending second-generation kits for preproduction evaluation and is working towards CE Mark approval, including a clinical investigation site in Australia. Achiko’s solutions aim to provide an effective alternative to traditional PCR testing, with benefits in cost, performance, and user experience.
Achiko AG has appointed David Hodge as the new Head of Corporate Development as of January 21, 2022, succeeding Christophe Laurent, who will retire on January 31, 2022. Hodge, a seasoned executive with over 30 years of experience across various sectors, including healthcare and technology, will focus on enhancing Achiko's corporate presence in Switzerland and oversee corporate affairs. His appointment comes as the company prepares for CE Mark registration of its Covid-19 rapid test, AptameX™, expected in Q1 2022, signaling a strategic move towards commercialization efforts beyond Indonesia.
Achiko AG (OTCQB: ACHKF) announced a feature article in The Jakarta Post about its Covid-19 saliva-based rapid test, AptameX™, aimed at improving testing accuracy and affordability in Indonesia. The article highlights Achiko's commitment to restoring trust in healthcare through innovative testing solutions. The company launched AptameX™ in mid-2021 and plans to submit a CE Mark approval application in 2022, showcasing its growth in the biotechnology space. Achiko operates globally with offices in Zurich, Hong Kong, Jakarta, Seoul, and Singapore.
Achiko AG has announced significant advancements in its AptameX™ Covid-19 saliva-based rapid test, achieving 100% sensitivity and specificity across various viral load ranges, with results confirmed from 58 human samples. The test outperformed conventional rapid tests, particularly in the critical CT value range of 25-33. Production scaling is underway, targeting one million kits per month, alongside the completion of the CE Mark for broader market access. These developments position AptameX as a cost-effective alternative to traditional testing methods, particularly beneficial for lower-income regions.
Achiko AG is finalizing a CHF 4.85 million funding from strategic investors, initiated in August 2021, to enhance its healthtech ecosystem and clear obligations to Yorkville Capital Management. The funds will aid in restructuring operational costs and advancing the commercialization of its Covid-19 rapid test, AptameX™, and its digital passport solution, Teman Sehat™. Additionally, Christophe Laurent will retire from the board, and Adam O’Keeffe is appointed as interim CFO. This strategic move comes as the company aims to strengthen its market position amid ongoing Covid-19 challenges.
Achiko AG, a healthtech company, marked 2021 as a pivotal year, launching its AptameX™ DNA aptamer saliva-based rapid test for Covid-19, approved in Indonesia for five years. The company aims to expand beyond Indonesia in 2022, targeting CE Mark registration and commercialization in Asia, the Middle East, and Eastern Europe. AptameX boasts a sensitivity of 77% at industry-standard CT scores of 28.3, outperforming many rapid tests. Production has begun with costs anticipated at around USD 0.60 per kit, with scaling expected to reduce costs further.
Achiko AG announces the launch of its AptameX™ Covid-19 testing solution, which utilizes DNA aptamer technology. This innovation aims to bridge the gap between rapid tests and PCR testing with greater accuracy and lower costs. The company's shares have been approved to trade on the OTCQB under the ticker symbol ACHKF. Achiko is also moving forward with its launch in Indonesia and plans to submit a CE Mark application for European markets. AptameX™ is designed to enhance community assurance through rapid, affordable testing.
FAQ
What is the market cap of ACHIKO NAMEN AKT (ACHKF)?
